Analysis Group, Inc., Boston, MA 02199, USA.
J Occup Environ Med. 2009 Oct;51(10):1167-76. doi: 10.1097/JOM.0b013e3181b8c397.
Rheumatoid arthritis (RA) greatly affects patients' abilities to perform work, which can translate into substantial employer costs. We developed a customizable model that allows employers to calculate workplace impacts of RA therapies in employees with RA.
Costs of medical leave (absenteeism)/disability, reduced productivity, job turnover, and work-equipment adaptations for employees with RA were calculated. Costs of the tumor necrosis factor antagonist adalimumab were compared with those of other RA treatments. Default parameters were based on literature, clinical trials, government sources, and employers' data.
Annual per-employee workplace cost was $9071 for adalimumab versus $16,335 for other RA therapies. Costs included reduced productivity (57%), absenteeism/disability (21%), and job turnover (21%).
RA imposes a large financial burden on employers, predominantly owing to lost productivity. When compared with other RA therapies, adalimumab substantially reduced employers' costs.
类风湿关节炎（RA）极大地影响了患者的工作能力，这可能给雇主带来巨大的成本。我们开发了一个可定制的模型，允许雇主计算 RA 治疗对患有 RA 的员工的工作场所的影响。
计算了患有 RA 的员工的医疗缺勤/残疾、生产力下降、工作变动以及工作设备调整的成本。比较了肿瘤坏死因子拮抗剂阿达木单抗与其他 RA 治疗方法的成本。默认参数基于文献、临床试验、政府来源和雇主数据。
阿达木单抗的每位员工每年工作场所成本为 9071 美元，而其他 RA 治疗方法为 16335 美元。成本包括生产力下降（57%）、缺勤/残疾（21%）和工作变动（21%）。
RA 给雇主带来了巨大的财务负担，主要是由于生产力下降。与其他 RA 治疗方法相比，阿达木单抗大幅降低了雇主的成本。
